- Home
- IDYA vs MNR Comparison
IDYA vs MNR Comparison
Compare IDYA & MNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- MNR
- Stock Information
- Founded
- IDYA 2015
- MNR 2017
- Country
- IDYA United States
- MNR United States
- Employees
- IDYA N/A
- MNR N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- MNR
- Sector
- IDYA Health Care
- MNR
- Exchange
- IDYA Nasdaq
- MNR Nasdaq
- Market Cap
- IDYA 2.0B
- MNR 1.7B
- IPO Year
- IDYA 2019
- MNR 2023
- Fundamental
- Price
- IDYA $21.67
- MNR $15.33
- Analyst Decision
- IDYA Strong Buy
- MNR Strong Buy
- Analyst Count
- IDYA 12
- MNR 3
- Target Price
- IDYA $54.27
- MNR $24.00
- AVG Volume (30 Days)
- IDYA 1.2M
- MNR 450.0K
- Earning Date
- IDYA 08-05-2025
- MNR 08-12-2025
- Dividend Yield
- IDYA N/A
- MNR 18.18%
- EPS Growth
- IDYA N/A
- MNR 705.75
- EPS
- IDYA N/A
- MNR 1.56
- Revenue
- IDYA $7,000,000.00
- MNR $941,846,000.00
- Revenue This Year
- IDYA $101.20
- MNR $4.44
- Revenue Next Year
- IDYA $286.70
- MNR $2.27
- P/E Ratio
- IDYA N/A
- MNR $9.81
- Revenue Growth
- IDYA N/A
- MNR 22.14
- 52 Week Low
- IDYA $13.45
- MNR $12.40
- 52 Week High
- IDYA $44.42
- MNR $20.94
- Technical
- Relative Strength Index (RSI)
- IDYA 58.21
- MNR 72.83
- Support Level
- IDYA $21.09
- MNR $12.91
- Resistance Level
- IDYA $22.50
- MNR $15.08
- Average True Range (ATR)
- IDYA 0.97
- MNR 0.40
- MACD
- IDYA -0.04
- MNR 0.23
- Stochastic Oscillator
- IDYA 56.44
- MNR 94.15
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About MNR Mach Natural Resources LP
Mach Natural Resources LP is an independent upstream oil and gas company. The company is focused on the acquisition, development and production of oil, natural gas, and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas, and the panhandle of Texas.